RVL Pharmaceuticals plc

OTCPK:RVLP.Q Rapporto sulle azioni

Cap. di mercato: US$111.0

RVL Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 1/6

RVL Pharmaceuticals ha un patrimonio netto totale di $16.3M e un debito totale di $57.7M, che porta il suo rapporto debito/patrimonio netto a 353.7%. Le sue attività totali e le sue passività totali sono rispettivamente $85.4M e $69.1M.

Informazioni chiave

353.7%

Rapporto debito/patrimonio netto

US$57.75m

Debito

Indice di copertura degli interessin/a
ContantiUS$19.16m
Patrimonio nettoUS$16.33m
Totale passivitàUS$69.08m
Totale attivitàUS$85.40m

Aggiornamenti recenti sulla salute finanziaria

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Apr 20
RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Jan 05
Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Recent updates

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 16
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

May 13
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

May 12
RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Apr 20
RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Jan 05
Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

Oct 18

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

Sep 22

RVL Pharma in pact with Revision Skincare to broaden access to products

Aug 30

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

Aug 11

RVL Pharma posts preliminary 42% sales growth for eye treatment

Jul 07

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

Jun 15

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Apr 01
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Mar 30

Osmotica: A Different Breed Of Cat

Dec 14

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Osmotica: Paring Down, Focusing On UPNEEQ

Jul 16

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { RVLP.Q di $25.8M ) non coprono le sue passività a breve termine ( $68.4M ).

Passività a lungo termine: Le attività a breve termine di RVLP.Q ( $25.8M ) superano le sue passività a lungo termine ( $686.0K ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 236.4% ) di RVLP.Q è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di RVLP.Q è aumentato da 75.8% a 353.7% negli ultimi 5 anni.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: Dati insufficienti per determinare se RVLP.Q ha una pista di cassa sufficiente in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Dati insufficienti per determinare se RVLP.Q ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.


Scoprire le aziende sane